Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study

Rhea-AI Summary

Nasus Pharma (NYSE: NSRX) will present topline analysis from the Phase 2 repeated dose clinical study of NS002, its intranasal powder epinephrine candidate, on March 16, 2026 at 8:00 a.m. ET. A question-and-answer session follows the data presentation.

Investors can join via live webcast (registration required) or dial-in, and a recording will be posted on the company investor relations website after the call.

News Market Reaction – NSRX

-15.43%

2 alerts

-15.43% News Effect

+12.4% Peak Tracked

-$10M Valuation Impact

$54M Market Cap

0.8x Rel. Volume

On the day this news was published, NSRX declined 15.43%, reflecting a significant negative market reaction. Argus tracked a peak move of +12.4% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $10M from the company's valuation, bringing the market cap to $54M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Topline call date: March 16, 2026 Topline call time: 8:00 a.m. ET

2 metrics

Topline call date March 16, 2026 Conference call to present Phase 2 NS002 topline analysis

Topline call time 8:00 a.m. ET Start time of NS002 Phase 2 topline webcast and Q&A

Market Reality Check

Price: $5.00 Vol: Volume 831 is well below ...

low vol

$5.00 Last Close

Volume Volume 831 is well below the 20-day average of 4,544, indicating limited pre-event positioning. low

Technical Shares at $4.86 are trading below the $7.07 200-day moving average and 51.35% under the 52-week high.

Peers on Argus

NSRX is down 2.61% while peers show mixed moves: SCLX up 2.66%, ASRT up 1.12%, M...

1 Down

NSRX is down 2.61% while peers show mixed moves: SCLX up 2.66%, ASRT up 1.12%, MIRA up 0.87%, MDCX down 33.98%, INCR down 3.51%. This points to stock-specific factors ahead of the NS002 update.

Common Catalyst Both NSRX and peer MDCX have clinical trial-related news flow, but price reactions differ and do not indicate a coordinated sector move.

Previous Clinical trial Reports

2 past events · Latest: Jan 20 (Positive)

Same Type Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Jan 20	Phase 2 interim data	Positive	-7.5%	Positive interim Phase 2 NS002 results with superior PK vs EpiPen.
Nov 06	Phase 2 approval	Positive	-0.7%	Health Canada clearance to initiate planned Phase 2 NS002 study.

Pattern Detected

Recent NSRX clinical-trial announcements have been positive but followed by share price declines, suggesting a pattern of negative reactions to favorable NS002 updates.

Recent Company History

Over recent months, Nasus Pharma has advanced NS002 through key clinical milestones. A Nov 6, 2025 Health Canada No-Objection Letter cleared initiation of the Phase 2 study. On Jan 20, 2026, the company reported positive interim Phase 2 results showing faster absorption and higher peak epinephrine levels versus EpiPen, yet the stock fell 7.52%. Today’s announcement of an upcoming Phase 2 topline presentation continues this NS002-focused clinical narrative.

Historical Comparison

-4.1% avg move · Past NS002 clinical-trial updates led to an average move of -4.09%, with shares declining after posi...

clinical trial

-4.1%

Average Historical Move clinical trial

Past NS002 clinical-trial updates led to an average move of -4.09%, with shares declining after positive Phase 2 milestones, framing expectations around this topline Phase 2 presentation.

NS002 has progressed from Health Canada Phase 2 clearance in Nov 2025, to positive interim Phase 2 data in Jan 2026, and now to a planned topline Phase 2 repeated-dose analysis call.

Market Pulse Summary

The stock dropped -15.4% in the session following this news. A negative reaction despite this schedu...

Analysis

The stock dropped -15.4% in the session following this news. A negative reaction despite this scheduling announcement fits a pattern where NSRX has traded lower after NS002 clinical milestones, including the Jan 20, 2026 interim data. Historical clinical-trial headlines saw an average move of -4.09%. Concerns about execution risk into full Phase 2 results or future pivotal trials could reinforce pressure, even though the current news mainly outlines a forthcoming topline discussion.

Key Terms

phase 2, intranasal, epinephrine, topline analysis, +2 more

6 terms

phase 2 medical

"topline analysis from the Phase 2 repeated dose clinical study of NS002"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

intranasal medical

"the Company’s intranasal powder epinephrine product candidate"

Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.

epinephrine medical

"the Company’s intranasal powder epinephrine product candidate"

Epinephrine, also known as adrenaline, is a fast-acting hormone and medication used to stimulate the heart, open airways and tighten blood vessels during life-threatening emergencies like severe allergic reactions, asthma attacks and cardiac arrest. Investors care because its clinical use and demand drive sales of drug products and delivery devices, influence regulatory approvals and supply chains, and can quickly affect revenue and stock value when shortages, new formulations or policy changes occur.

topline analysis medical

"to present and discuss the topline analysis from the Phase 2 repeated dose"

A topline analysis is a high-level review of a company's most important headline numbers—typically sales (revenue), profit margins and other primary results—meant to show whether the business is growing or shrinking. It matters to investors because it provides a quick snapshot of performance and momentum, helping decide whether to investigate further or adjust valuations, much like glancing at a car’s speedometer to judge whether you need to slow down or speed up.

clinical study medical

"topline analysis from the Phase 2 repeated dose clinical study of NS002"

A clinical study is a research process that tests how well a new medicine, treatment, or medical device works and whether it is safe for people. It often involves volunteers and follows a structured plan to gather evidence about the product’s effectiveness. For investors, clinical studies are important because successful results can lead to new products, increased sales, and potential growth for the companies involved.

webcast technical

"host a conference call and webcast on Monday, March 16, 2026"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that members of the Company’s management will host a conference call and webcast on Monday, March 16, 2026, at 8:00 a.m. ET to present and discuss the topline analysis from the Phase 2 repeated dose clinical study of NS002, the Company’s intranasal powder epinephrine product candidate. A question-and-answer session will follow the data presentation.

Conference call & webcast info:

• Monday, March 16, 2026, at 08:00 a.m. ET
  
  
• Individuals may register for the webcast at the following link: Webcast registration (https://viavid.webcasts.com/starthere.jsp?ei=1755620&tp_key=9fc412bf2a)
• Dial-in numbers for the conference call are:
  US: 1-877-704-4453
  International: 1-201-389-0920

Following the conference call, a recording of the webcast will be available on Nasus Pharma’s investor relations website at https://ir.nasuspharma.com/investors/events/.

About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’ intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus’ proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or LinkedIn.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements.  For example, Nasus Pharma is using forward-looking statements in this press release when it discusses: its expected announcement of the topline analysis of the data from its Phase 2 repeated dose clinical study of NS002, and its hosting of a conference call to discuss such results. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Registration Statement on Form F-1 filed with the United States Securities and Exchange Commission on March 2, 2026. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Company Contact
Nasus Pharma Ltd.
info@nasuspharma.com

Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com

FAQ

When will Nasus Pharma (NSRX) present topline NS002 Phase 2 results?

Nasus Pharma will present topline Phase 2 NS002 results on March 16, 2026 at 8:00 a.m. ET. According to the company, management will discuss the topline analysis from the repeated dose study and host a live question-and-answer session after the presentation.

How can investors register for the Nasus Pharma (NSRX) webcast for the March 16, 2026 presentation?

Investors can register for the webcast using the provided online registration link before the event. According to the company, registrants will access the live webcast and a recording will be available afterward on Nasus Pharma’s investor relations website.

What will Nasus Pharma (NSRX) discuss about NS002 during the March 16, 2026 call?

The company will present the topline analysis from the Phase 2 repeated dose clinical study of NS002 and answer questions. According to the company, management will review study toplines and follow with a question-and-answer session for investors and analysts.

How can attendees join the Nasus Pharma (NSRX) conference call if they prefer phone access?

Attendees may join the conference call via provided US and international dial-in numbers for the March 16, 2026 event. According to the company, dial-in details are published with the webcast registration information for live participation.

Where will the Nasus Pharma (NSRX) webcast recording be available after the March 16, 2026 presentation?

A recording of the webcast will be posted on Nasus Pharma’s investor relations website following the conference call. According to the company, the recording will be accessible at the company’s events page for later review by investors.